Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1981 1
2006 2
2007 2
2008 4
2009 2
2010 3
2011 1
2012 1
2013 4
2014 4
2015 6
2016 4
2017 3
2018 5
2019 7
2020 6
2021 11
2022 8
2023 18
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, Lako A, Tsuji J, Liu Y, Brennick RC, Gentzler RD, Lee C, Hubbard J, Arnold SM, Abbruzzese JL, Jabbour SK, Uboha NV, Stephans KL, Johnson JM, Park H, Villaruz LC, Sharon E, Streicher H, Ahmed MM, Lyon H, Cibuskis C, Lennon N, Jhaveri A, Yang L, Altreuter J, Gunasti L, Weirather JL, Mak RH, Awad MM, Rodig SJ, Chen HX, Wu CJ, Monjazeb AM, Hodi FS. Schoenfeld JD, et al. Among authors: jhaveri a. Lancet Oncol. 2022 Feb;23(2):279-291. doi: 10.1016/S1470-2045(21)00658-6. Epub 2022 Jan 13. Lancet Oncol. 2022. PMID: 35033226 Free PMC article. Clinical Trial.
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease.
Penter L, Liu Y, Wolff JO, Yang L, Taing L, Jhaveri A, Southard J, Patel M, Cullen NM, Pfaff KL, Cieri N, Oliveira G, Kim-Schulze S, Ranasinghe S, Leonard R, Robertson T, Morgan EA, Chen HX, Song MH, Thurin M, Li S, Rodig SJ, Cibulskis C, Gabriel S, Bachireddy P, Ritz J, Streicher H, Neuberg DS, Hodi FS, Davids MS, Gnjatic S, Livak KJ, Altreuter J, Michor F, Soiffer RJ, Garcia JS, Wu CJ. Penter L, et al. Among authors: jhaveri a. Blood. 2023 Apr 13;141(15):1817-1830. doi: 10.1182/blood.2022018246. Blood. 2023. PMID: 36706355 Free PMC article.
Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy.
Kaczanowska S, Murty T, Alimadadi A, Contreras CF, Duault C, Subrahmanyam PB, Reynolds W, Gutierrez NA, Baskar R, Wu CJ, Michor F, Altreuter J, Liu Y, Jhaveri A, Duong V, Anbunathan H, Ong C, Zhang H, Moravec R, Yu J, Biswas R, Van Nostrand S, Lindsay J, Pichavant M, Sotillo E, Bernstein D, Carbonell A, Derdak J, Klicka-Skeels J, Segal JE, Dombi E, Harmon SA, Turkbey B, Sahaf B, Bendall S, Maecker H, Highfill SL, Stroncek D, Glod J, Merchant M, Hedrick CC, Mackall CL, Ramakrishna S, Kaplan RN. Kaczanowska S, et al. Among authors: jhaveri a. Cancer Cell. 2024 Jan 8;42(1):35-51.e8. doi: 10.1016/j.ccell.2023.11.011. Epub 2023 Dec 21. Cancer Cell. 2024. PMID: 38134936
ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
Prabhu VV, Morrow S, Rahman Kawakibi A, Zhou L, Ralff M, Ray J, Jhaveri A, Ferrarini I, Lee Y, Parker C, Zhang Y, Borsuk R, Chang WI, Honeyman JN, Tavora F, Carneiro B, Raufi A, Huntington K, Carlsen L, Louie A, Safran H, Seyhan AA, Tarapore RS, Schalop L, Stogniew M, Allen JE, Oster W, El-Deiry WS. Prabhu VV, et al. Among authors: jhaveri a. Neoplasia. 2020 Dec;22(12):725-744. doi: 10.1016/j.neo.2020.09.005. Epub 2020 Oct 23. Neoplasia. 2020. PMID: 33142238 Free PMC article. Review.
Tutorial: integrative computational analysis of bulk RNA-sequencing data to characterize tumor immunity using RIMA.
Yang L, Wang J, Altreuter J, Jhaveri A, Wong CJ, Song L, Fu J, Taing L, Bodapati S, Sahu A, Tokheim C, Zhang Y, Zeng Z, Bai G, Tang M, Qiu X, Long HW, Michor F, Liu Y, Liu XS. Yang L, et al. Among authors: jhaveri a. Nat Protoc. 2023 Aug;18(8):2404-2414. doi: 10.1038/s41596-023-00841-8. Epub 2023 Jun 30. Nat Protoc. 2023. PMID: 37391666 Review.
Single-cell heterogeneity of EGFR and CDK4 co-amplification is linked to immune infiltration in glioblastoma.
Walentynowicz KA, Engelhardt D, Cristea S, Yadav S, Onubogu U, Salatino R, Maerken M, Vincentelli C, Jhaveri A, Geisberg J, McDonald TO, Michor F, Janiszewska M. Walentynowicz KA, et al. Among authors: jhaveri a. Cell Rep. 2023 Mar 28;42(3):112235. doi: 10.1016/j.celrep.2023.112235. Epub 2023 Mar 14. Cell Rep. 2023. PMID: 36920905 Free PMC article.
Idiopathic intracranial hypertension in atypical demographics.
Donaldson L, Jhaveri A, Micieli J, Margolin E. Donaldson L, et al. Among authors: jhaveri a. J Neurol Sci. 2022 Jun 15;437:120271. doi: 10.1016/j.jns.2022.120271. Epub 2022 Apr 29. J Neurol Sci. 2022. PMID: 35525063
82 results